Skip to main content
. 2019 Mar 27;21(4):413–427. doi: 10.1016/j.neo.2019.03.003

Figure S2.

Figure S2

LOXL2 promotes lymphangiogenesis in clinical cancer specimens and breast cancer mice models. (A) Associations of LOXL2 IHC scores with tumor stage (I, II, III-IV) (B) Specimens were subsequently classified into 4 groups: positive expression level of LOXL2 with lymph node metastasis, negative expression level of LOXL2 with no lymph node metastasis, positive expression level of LOXL2 with no lymph node metastasis, negative expression level of LOXL2 with lymph node metastasis. (C) Associations of LYVE-1 IHC scores with tumor stage (I, II, III-IV). (D) Specimens were subsequently classified into 4 groups: positive expression level of LYVE-1 with lymph node metastasis, negative expression level of LYVE-1 with no lymph node metastasis, positive expression level of LYVE-1 with no lymph node metastasis, negative expression level of LYVE-1 with lymph node metastasis. (E) The protein levels of LOXL2 in the MCF-7 and MDA-MB-231 cells lysis and CM were measured by immunoblot, respectively. (F) Quantification results of IF staining area of LYVE-1 and podoplanin in panel G. (G) LYVE-1 and podoplanin expression detected by IF staining in primary tumors from xenograft-bearing mice injected with MCF-7 cells and MDA-MB-231 cells (n = 6). Columns: means ± SDs. **P < .01; ***P < .001. Scale bar = 100 μm.